Figure 2.

Western Blot of Lysates of BCPAP, K1, and BHP 2-7 Treated with 0.05 μM Panobinostat and 0.1 μM Dabrafenib/2.5 μM Selumetinib Individually or in Combination for 48 h

DMSO was used as the vehicle control. In (A), cells were treated with panobinostat and dabrafenib alone or in combination; in (B), cells were treated with panobinostat and selumetinib individually or in combination. Both panobinostat and panobinostat combined with dabrafenib/selumenitib can induce histone H3 acetylation in the three cell lines, but there was no distinct difference of global acetylation of histone H3 between HDACi alone and HDACi combined with MAPKi. In addition, they have no effect on ERK1/2 phosphorylation. Dabrafenib and selumetinib block ERK1/2 phosphorylation in BCPAP and K1, but they have no effect in BHP2-7. Besides, it has no effect on histone H3 acetylation. Con, DMSO control; Pa, panobinostat; Da, dabrafenib; Se, selumetinib.